Vardenafil as add-on Therapy for Patients With Pulmonary Hypertension Treated With Inhaled Iloprost

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2012 by Rabin Medical Center.
Recruitment status was  Not yet recruiting
Sponsor:
Information provided by (Responsible Party):
Mordechai Kremer, Rabin Medical Center
ClinicalTrials.gov Identifier:
NCT01649739
First received: July 22, 2012
Last updated: July 24, 2012
Last verified: July 2012
  Purpose

Patients with pulmonary arterial hypertension (PAH) suffer from breathlessness, poor quality of life and inability to function, despite medical therapy Current consensus states that combination therapy with different classes of PAH-specific therapy is likely to bring additional benefit to PAH patients. In this study we plan to study how exercise performance changes when the phosphodiesterase inhibitor vardenafil is added to patients who remain symptomatic from PAH when treated with inhaled iloprost.

Following baseline assessment, all Patients will start vardenafil 10 mg bid. If the drug is tolerated by the patients, after a two week period, up titration to 20 mg bid will be permitted, at the discretion of the investigators.

According to treatment protocol up titration will be done carefully and whenever side effects will be reported up titration will be stopped or dosage will be decreased or stopped according to the investigator judgment.

Systemic BP will be measured at baseline assessment. The patient will attend the clinic for the first dose monitoring (10 mg) and after up titration of the study drug to 20 mg.

Systemic BP will be measured at baseline assessment. The patient will attend the clinic for the first dose monitoring (10 mg) and after up titration of the study drug to 20 mg. A fall in SBP of>30 mmHg will be considered significant or any smaller value at the discretion of the investigator. BP will be measured according to the following protocol.

Pre-dose Immediately before administration of vardenafil. This will be timed approximately one hour prior to the next planned dose of iloprost.

Pre-inhalation One hour post vardenafil dose, immediately prior to iloprost inhalation.

Post-inhalation Immediately following completion of iloprost inhalation and every fifteen minutes for one hour.

Prior to discharge Two hours following the iloprost.

Later monitoring At all follow-up visits, BP will be measured.

This is an open-label study to evaluate the safety and efficacy of adding higher doses of vardenafil to inhaled iloprost over 3 months.


Condition Intervention Phase
Pulmonary Arterial Hypertension
Drug: Levitra
Phase 4

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by Rabin Medical Center:

Primary Outcome Measures:
  • Change in 6 minute walk or New York Heart Association functional class. [ Time Frame: 14 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Changes in Pulmonary artery pressure assessed (by echo), exercise test parameters, pro-NT BNP, quality of life. Clinical worsening during study, study drop-out and adverse events during the study. [ Time Frame: 14 weeks ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 20
Study Start Date: September 2012
Estimated Study Completion Date: January 2014
Estimated Primary Completion Date: May 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Levitra Drug: Levitra
There is 2 dosage:10mg Twice daily and 20mg Twice daily

  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. All Patients must satisfy current diagnostic criteria for pulmonary artery hypertension based on their historical right heart catheter data (within 3 years of study enrollment): Mean PAP≥25mmHg at rest by a PCWP<15mmHg and by PVR >3 Wood Units.
  2. Currently stable for at least 3 months with inhaled iloprost, between 5-9 doses per day, using the I-Neb device.
  3. Willing and able to participate in all study follow-up procedures.
  4. New York Heart Association (NYHA) Class II-IV.
  5. Six minute walking distance between 100-450 meters at the baseline assessment.
  6. Women of child-bearing age must demonstrate adequate contraception or undergo a pregnancy test.
  7. Patients with inoperable pulmonary thromboembolic disease or congenital heart disease are eligible for inclusion.

Exclusion Criteria:

  1. Functional Class NYHA Class I.
  2. PAH due to left heart disease, chronic lung diseases (VC or FEV1 <60% of predicted), chronic hypoxia or chronic thromboembolic disease.
  3. Acute intercurrent illness requiring hospital admission in the month proceeding screening.
  4. Any non-PAH medical condition likely to interfere with participation in evaluation of study endpoints, e.g. musculoskeletal disorders.
  5. Any uncontrolled or terminal non-PAH medical condition likely to interfere with completion of the study, according to the judgment of the study physician.
  6. Concomitant therapy with drugs known to interact adversely with the study drug (Nitrates, alpha-adrenergic receptor antagonists, CYP3A4 inhibitors (HIV protease inhibitors, ketoconazole, itraconazole, erythromycin
  7. Chronic renal failure - creatinine clearance< 50ml/min as calculated with the Cockcroft equation.
  8. Current participation in another clinical trial.
  9. Pregnancy or planned pregnancy during the study period.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01649739

Contacts
Contact: Mordechai R Kramer, MD 972-505710702 kremerm@clalit.org.il
Contact: Dror Rosengarten, MD 972-542174321 drorro@clalit.org.il

Locations
Israel
Pulmonary Institute,Rabin Medical Center Not yet recruiting
Petach Tikva, Israel, 49100
Contact: Mordechai R Kramer, MD    972-39377221    kremerm@clalit.org.il   
Principal Investigator: Mordechai R Kramer, MD         
Sponsors and Collaborators
Rabin Medical Center
  More Information

No publications provided

Responsible Party: Mordechai Kremer, Profesor, Rabin Medical Center
ClinicalTrials.gov Identifier: NCT01649739     History of Changes
Other Study ID Numbers: RMCVAR1234
Study First Received: July 22, 2012
Last Updated: July 24, 2012
Health Authority: Israel: Ministry of Health

Keywords provided by Rabin Medical Center:
PAH

Additional relevant MeSH terms:
Hypertension, Pulmonary
Hypertension
Lung Diseases
Respiratory Tract Diseases
Vascular Diseases
Cardiovascular Diseases
Vardenafil
Vasodilator Agents
Cardiovascular Agents
Therapeutic Uses
Pharmacologic Actions
Phosphodiesterase 5 Inhibitors
Phosphodiesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Urological Agents

ClinicalTrials.gov processed this record on August 20, 2014